Lexicon Pharmaceuticals, Inc. (LXRX)
LXRXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.86
+0.0400 (+2.20%) today
At the close, Nov 10, 4:00 PM ET. After hours $1.89 +1.61%
- Market cap
- $828.14m
- P/E
- –
- EPS, last 4 quarters
- $-0.1300
- Dividend yield
- –
- Day range
- $1.80 to $1.96
- 52-week range
- $1.10 to $2.68
- Average volume
- 2.64m
- Previous close
- $1.82
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $5.85, +214.5% from here
Earnings
next estimate $-0.0400Next report
Dec 2025
+42.9%
Mar 2026
+100.0%
Jun 2026
0.0%
Sep 2026
+50.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $5.49m | $21.10m | $692.0k | $11.25m |
| Gross profit | $5.29m | $20.99m | $653.0k | $11.17m |
| Operating income | -$14.78m | -$996.0k | -$26.54m | -$14.49m |
| Net income | -$15.53m | -$1.04m | -$31.77m | -$14.01m |
Last four quarters: revenue $38.54m, margin -161.8%, free cash flow –
News
8 latest- What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings CallMarketBeat · 5 days ago
- Lexicon Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial ResultsFintel · 5 days ago
- Lexicon (LXRX) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue EstimatesZacks · 5 days ago
- Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue EstimatesZacks · 6 days ago
- Lexicon Pharmaceuticals Consensus Price Target Increased by 17.91% to $4.64Fintel · Oct 1, 2026
- Why Lexicon Pharmaceuticals Stock Popped by Almost 6% TodayThe Motley Fool · Sep 28, 2026
- Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin DataMarketBeat · Sep 20, 2026
The company
Lexicon Pharmaceuticals is a biopharmaceutical company pursuing novel medicines for patients with serious cardiometabolic diseases. Building on a proven legacy in genetic target discovery, Lexicon is advancing a clinical pipeline in areas of significant and often underserved need, with programs in hypertrophic cardiomyopathy (HCM), type 1 diabetes (T1D), obesity and other related metabolic conditions. Lexicon is committed to developing differentiated therapies that can be integrated broadly into clinical practice, with the goal of expanding treatment options for patients. Its capabilities extend from early-stage target discovery through clinical development and commercialization, strategically paired with high-impact collaborations to maximize the global reach of its medicines.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- lexpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.